Inhibiting NETs in vivo, either through PAD4-deficient mice or treatment with DNase I, leads to reduced activity of regulatory T cells (Tregs) in NASH, and depletion of Tregs significantly inhibits the initiation and progression of HCC (119). Here, PADI4 is linked to metabolic dysfunction-associated steatohepatitis.